TIDMIMM

RNS Number : 6189J

Immupharma PLC

24 August 2021

24 August 2021

ImmuPharma PLC

("ImmuPharma" or the "Company")

Director & PDMR Share Purchases

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that each member of the Board of Directors and PDMR, Ewa Flynn (Chief Financial Officer) have on 23 & 24 August 2021 purchased in total 670,000 ordinary shares of 10p in the Company ("Ordinary Shares").

Details of the share purchases by the Board and their current interests in shares following the transactions are set out below.

 
 NAME & TITLE              ORDINARY SHARES     NUMBER OF ORDINARY   % OF ISSUED SHARE 
                            PURCHASED           SHARES HELD POST     CAPITAL 
                            & PURCHASE PRICE    TRANSACTION 
 Tim McCarthy 
  Chairman & Chief 
  Executive Officer        250,000 @ 8.26p     288,462              0.12% 
                          ------------------  -------------------  ------------------ 
 Dr Tim Franklin 
  Chief Operating 
  Officer                  125,000 @ 7.99p     125,000              0.05% 
                          ------------------  -------------------  ------------------ 
 Dr Sanjeev Pandya 
  Senior Non-Executive 
  Director                 125,000 @ 8.00p     125,000              0.05% 
                          ------------------  -------------------  ------------------ 
 Lisa Baderoon 
  Non-Executive 
  Director & Head 
  of Investor Relations    140,000 @ 8.1957p   183,963              0.07% 
                          ------------------  -------------------  ------------------ 
 Ewa Flynn 
  Chief Financial 
  Officer & 
  Company Secretary        30,000 @ 7.892p     30,000               0.01% 
                          ------------------  -------------------  ------------------ 
 

Full disclosure of the transactions by persons discharging managerial responsibilities and persons closely associated with them ("PDMR's") are detailed at the end of the announcement.

End

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. on publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 
 For further information please contact: 
   ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chairman and Chief Executive 
    Officer                                       + 44 (0) 207 152 4080 
   Dr Tim Franklin, Chief Operating Officer 
   Lisa Baderoon, Head of Investor Relations      + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin                                  +44 (0) 203 36 8 3550 
 
    Stanford Capital Partners (Joint Broker) 
    Patrick Claridge                               +44 (0) 203 815 8880 
    John Howes 
    Bob Pountney 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                   +44 (0) 1483 413500 
   4Reliance (Euronext Growth Listing Sponsor)    +32 (0) 2 747 02 60 
    Jean-Charles Snoy 
 
    Degroof Petercam (Liquidity Provider)          +32 (0) 2 287 95 34 
    Erik De Clippel 
 
    Backstage Communication 
    Olivier Duquaine                               +32 (0) 477 504 784 
    Gunther De Backer                              +32 (0) 475 903 909 
 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase 3 trial for Lupuzor(TM) and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 
  1    Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                        Tim McCarthy 
      ------------------------------------------  ------------------------------------------- 
  2    Reason for the notification 
      --------------------------------------------------------------------------------------- 
 a)    Position / status                           Chairman and Chief Executive Officer 
      ------------------------------------------  ------------------------------------------- 
 b)    Initial notification                        Initial notification 
        / Amendment 
      ------------------------------------------  ------------------------------------------- 
  3    Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------------------- 
 a)    Name                                        ImmuPharma PLC 
      ------------------------------------------  ------------------------------------------- 
 b)    LEI                                         213800VZKGHXC7VUS895 
      ------------------------------------------  ------------------------------------------- 
  4    Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      --------------------------------------------------------------------------------------- 
 a)    Description of the                          Ordinary Shares of 10p each 
        financial instrument 
        , type of instrument 
                                                    ISIN: GB0033711010 
        Identification code 
      ------------------------------------------  ------------------------------------------- 
 b)    Nature of the transaction                   On-market purchase 
      ------------------------------------------  ------------------------------------------- 
 c)    Price(s) and volume(s)                            Price                 Volume 
      ------------------------------------------  ------------------  ----------------------- 
                                                         8.26p                250,000 
 -----------------------------------------------  ------------------  ----------------------- 
 d)    Aggregated information 
 
        - Aggregated volume 
 
        - Price 
      ------------------------------------------  ------------------------------------------- 
 e)    Date of the transaction                     23 August 2021 
      ------------------------------------------  ------------------------------------------- 
 f)    Place of the transaction                    London Stock Exchange, AIM Market (XLON) 
      ------------------------------------------  ------------------------------------------- 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 
  1    Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                        Dr Tim Franklin 
      ------------------------------------------  ------------------------------------------- 
  2    Reason for the notification 
      --------------------------------------------------------------------------------------- 
 a)    Position / status                           Chief Operating Officer 
      ------------------------------------------  ------------------------------------------- 
 b)    Initial notification                        Initial notification 
        / Amendment 
      ------------------------------------------  ------------------------------------------- 
  3    Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------------------- 
 a)    Name                                        ImmuPharma PLC 
      ------------------------------------------  ------------------------------------------- 
 b)    LEI                                         213800VZKGHXC7VUS895 
      ------------------------------------------  ------------------------------------------- 
  4    Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      --------------------------------------------------------------------------------------- 
 a)    Description of the                          Ordinary Shares of 10p each 
        financial instrument 
        , type of instrument 
                                                    ISIN: GB0033711010 
        Identification code 
      ------------------------------------------  ------------------------------------------- 
 b)    Nature of the transaction                   On-market purchase 
      ------------------------------------------  ------------------------------------------- 
 c)    Price(s) and volume(s)                            Price                 Volume 
      ------------------------------------------  ------------------  ----------------------- 
                                                         7.99p                125,000 
 -----------------------------------------------  ------------------  ----------------------- 
 d)    Aggregated information 
 
        - Aggregated volume 
 
        - Price 
      ------------------------------------------  ------------------------------------------- 
 e)    Date of the transaction                     24 August 2021 
      ------------------------------------------  ------------------------------------------- 
 f)    Place of the transaction                    London Stock Exchange, AIM Market (XLON) 
      ------------------------------------------  ------------------------------------------- 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 
  1    Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                        Dr Sanjeev Pandya 
      ------------------------------------------  ------------------------------------------- 
  2    Reason for the notification 
      --------------------------------------------------------------------------------------- 
 a)    Position / status                           Senior Non-Executive Director 
      ------------------------------------------  ------------------------------------------- 
 b)    Initial notification                        Initial notification 
        / Amendment 
      ------------------------------------------  ------------------------------------------- 
  3    Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------------------- 
 a)    Name                                        ImmuPharma PLC 
      ------------------------------------------  ------------------------------------------- 
 b)    LEI                                         213800VZKGHXC7VUS895 
      ------------------------------------------  ------------------------------------------- 
  4    Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      --------------------------------------------------------------------------------------- 
 a)    Description of the                          Ordinary Shares of 10p each 
        financial instrument 
        , type of instrument 
                                                    ISIN: GB0033711010 
        Identification code 
      ------------------------------------------  ------------------------------------------- 
 b)    Nature of the transaction                   On-market purchase 
      ------------------------------------------  ------------------------------------------- 
 c)    Price(s) and volume(s)                            Price                 Volume 
      ------------------------------------------  ------------------  ----------------------- 
                                                          8p                  125,000 
 -----------------------------------------------  ------------------  ----------------------- 
 d)    Aggregated information 
 
        - Aggregated volume 
 
        - Price 
      ------------------------------------------  ------------------------------------------- 
 e)    Date of the transaction                     23 August 2021 
      ------------------------------------------  ------------------------------------------- 
 f)    Place of the transaction                    London Stock Exchange, AIM Market (XLON) 
      ------------------------------------------  ------------------------------------------- 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 
  1    Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                      Lisa Baderoon 
      ----------------------------------------  -------------------------------------------- 
  2    Reason for the notification 
      -------------------------------------------------------------------------------------- 
 a)    Position / status                         Non-Executive Director & Head of Investor 
                                                  Relations 
      ----------------------------------------  -------------------------------------------- 
 b)    Initial notification                      Initial notification 
        / Amendment 
      ----------------------------------------  -------------------------------------------- 
  3    Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------------------- 
 a)    Name                                      ImmuPharma PLC 
      ----------------------------------------  -------------------------------------------- 
 b)    LEI                                       213800VZKGHXC7VUS895 
      ----------------------------------------  -------------------------------------------- 
  4    Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      -------------------------------------------------------------------------------------- 
 a)    Description of the                        Ordinary Shares of 10p each 
        financial instrument 
        , type of instrument 
                                                  ISIN: GB0033711010 
        Identification code 
      ----------------------------------------  -------------------------------------------- 
 b)    Nature of the transaction                 On-market purchase 
      ----------------------------------------  -------------------------------------------- 
 c)    Price(s) and volume(s)                            Price                 Volume 
      ----------------------------------------  ----------------------  -------------------- 
                                                        8.1957p                140,000 
 ---------------------------------------------  ----------------------  -------------------- 
 d)    Aggregated information 
 
        - Aggregated volume 
 
        - Price 
      ----------------------------------------  -------------------------------------------- 
 e)    Date of the transaction                   23 August 2021 
      ----------------------------------------  -------------------------------------------- 
 f)    Place of the transaction                  London Stock Exchange, AIM Market (XLON) 
      ----------------------------------------  -------------------------------------------- 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 
  1    Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                        Ewa Flynn 
      ------------------------------------------  ------------------------------------------- 
  2    Reason for the notification 
      --------------------------------------------------------------------------------------- 
 a)    Position / status                           Chief Financial Officer (PDMR) 
      ------------------------------------------  ------------------------------------------- 
 b)    Initial notification                        Initial notification 
        / Amendment 
      ------------------------------------------  ------------------------------------------- 
  3    Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------------------- 
 a)    Name                                        ImmuPharma PLC 
      ------------------------------------------  ------------------------------------------- 
 b)    LEI                                         213800VZKGHXC7VUS895 
      ------------------------------------------  ------------------------------------------- 
  4    Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      --------------------------------------------------------------------------------------- 
 a)    Description of the                          Ordinary Shares of 10p each 
        financial instrument 
        , type of instrument 
                                                    ISIN: GB0033711010 
        Identification code 
      ------------------------------------------  ------------------------------------------- 
 b)    Nature of the transaction                   On-market purchase 
      ------------------------------------------  ------------------------------------------- 
 c)    Price(s) and volume(s)                              Price                 Volume 
      ------------------------------------------  ----------------------  ------------------- 
                                                          7.892p                 30,000 
 -----------------------------------------------  ----------------------  ------------------- 
 d)    Aggregated information 
 
        - Aggregated volume 
 
        - Price 
      ------------------------------------------  ------------------------------------------- 
 e)    Date of the transaction                     23 August 2021 
      ------------------------------------------  ------------------------------------------- 
 f)    Place of the transaction                    London Stock Exchange, AIM Market (XLON) 
      ------------------------------------------  ------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHPIMMTMTMTBAB

(END) Dow Jones Newswires

August 24, 2021 06:07 ET (10:07 GMT)

Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Nov 2021 a Dic 2021 Haga Click aquí para más Gráficas Immupharma.
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Dic 2020 a Dic 2021 Haga Click aquí para más Gráficas Immupharma.